The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience.
N. Caristi
No relevant relationships to disclose
T. Franchina
No relevant relationships to disclose
C. Proto
No relevant relationships to disclose
G. Chiofalo
No relevant relationships to disclose
G. Toscano
No relevant relationships to disclose
A. Scimone
No relevant relationships to disclose
M. Zanghì
No relevant relationships to disclose
R. Berenato
No relevant relationships to disclose
R. Briguglio
No relevant relationships to disclose
N. Denaro
No relevant relationships to disclose
L. Noto
No relevant relationships to disclose
V. Adamo
No relevant relationships to disclose